476 related articles for article (PubMed ID: 21807639)
1. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
2. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
3. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
[TBL] [Abstract][Full Text] [Related]
5. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.
Shiroiwa T; Motoo Y; Tsutani K
Mol Diagn Ther; 2010 Dec; 14(6):375-84. PubMed ID: 21275455
[TBL] [Abstract][Full Text] [Related]
8. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
12. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Behl AS; Goddard KA; Flottemesch TJ; Veenstra D; Meenan RT; Lin JS; Maciosek MV
J Natl Cancer Inst; 2012 Dec; 104(23):1785-95. PubMed ID: 23197490
[TBL] [Abstract][Full Text] [Related]
15. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
18. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
20. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
